$11.6 Billion Application Platform Market - Global Forecast to 2023

June 5, 2018, 4:18 am

≫ Next: Iran tells UN it will hike uranium enrichment capacity, says move does not mean negotiations with Europe have failed

≪ Previous: Next two Galileos plus launcher at Europe’s Spaceport for July launch

$

0

0

Dublin, June 05, 2018 (GLOBE NEWSWIRE) -- The "Application Platform Market by Software (App Platform & Transaction Processing Monitor), Service (Deployment & Integration, Support & Maintenance, & Managed), Deployment (aPaaS & On-Premises), Organization Size, & Region - Global Forecast to 2023" report has been added to *ResearchAndMarkets.com's* offering.The global application platform market size is expected to grow from USD 8.99 billion in 2018 to USD 11.69 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 5.4% during the forecast period.The factors such as the rising importance of DevOps and Application Platform-as-Service (aPaaS) is driving the growth of the application platform market. However, competition from open-source alternatives is restraining the application platform market growth.

The aPaaS segment is active, competitive, and rapidly growing, which is said to be gaining traction. This trend is expected to continue during the forecast period. aPaaS is also called as the third-party provider-managed platform and is majorly offered as cloud services. This segment offers a development and deployment environment for application platform services. Moreover, aPaaS delivers fast, secure, and business-critical enterprise applications with a low Capital Expenditure (CapEx) and upfront cost. aPaaS also manages the complete life cycle of application platforms, starting from building, testing, deploying, and managing to updating.

North America is expected to account for the largest market size in the application platform market during the forecast period. With regards to the emergence of trending technologies, such as Software-as-Service (SaaS)-based applications, cloud computing, big data, DevOps, and enterprise mobility, users and enterprises have been urged to adopt much more sophisticated and reliable application platform software and associated services. This adoption is expected to contribute to the overall growth of the application platform market in North America.

Asia Pacific (APAC) is expected to witness significant growth and projected to be the fastest-growing region in the global application platform market during the forecast period. The region has witnessed the advanced and dynamic adoption of new technologies and has been a lucrative market for application platform software and associated services. Owing to the rapid growth of web and mobile applications in this region, the need to deploy, monitor, protect, and manage these applications against vulnerabilities is a major concern. This concern has given rise to the demand for application platform software in this region, as this software provides a reliable platform to develop, deploy, and manage enterprise applications.*Key Topics Covered:**1 Introduction*

*2 Research Methodology*

*3 Executive Summary *

*4 Premium Insights*
4.1 Attractive Market Opportunities in the Application Platform Market
4.2 Market By Service and Region, 2018
4.3 Market Investment Scenario, 2018-2023
4.4 Market By Organization Size, 2018
4.5 Market By Region, 2018 vs 2023

*5 Market Overview*
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Demand for Collaborative Application Development
5.2.1.2 Importance of Devops
5.2.1.3 Emergence of No-Code Application Platforms
5.2.1.4 Rise of Apaas
5.2.2 Restraints
5.2.2.1 Competition From Open-Source Alternatives
5.2.3 Opportunities
5.2.3.1 Advancements in Application Delivery and the Evolution of Software-Defined Age
5.2.4 Challenges
5.2.4.1 Lack of Pro-Active and Real-Time Application Visibility
5.2.4.2 Lack of Skill Set and Expertise
5.3 Application Platform-As-A-Service: Types
5.3.1 High-Productivity Application Platform-As-A-Service
5.3.2 High-Control Application Platform-As-A-Service

*6 Application Platform Market, By Component*
6.1 Introduction
6.2 Software
6.3 Services

*7 Market By Software*
7.1 Introduction
7.2 Application Platform Software
7.3 Transaction Processing Monitor Software

*8 Market By Service*
8.1 Introduction
8.2 Deployment and Integration
8.3 Support and Maintenance
8.4 Managed Services

*9 Application Platform Market, By Deployment*
9.1 Introduction
9.2 On-Premises
9.3 Application Platform-As-A-Service

*10 Market By Organization Size*
10.1 Introduction
10.2 Small and Medium-Sized Enterprises
10.3 Large Enterprises

*11 Application Platform Market, By Region*
11.1 Introduction
11.2 North America
11.3 Europe
11.4 Asia Pacific
11.5 Middle East and Africa
11.6 Latin America

*12 Competitive Landscape*
12.1 Overview
12.2 Market Ranking Analysis
12.3 Competitive Scenario
12.3.1 New Product Launches
12.3.2 Mergers and Acquisitions
12.3.3 Agreements and Partnerships

*13 Company Profiles*
13.1 IBM
13.2 SAP
13.3 NEC
13.4 Micro Focus
13.5 Oracle
13.6 Fujitsu
13.7 Microsoft
13.8 Hitachi
13.9 Adobe Systems
13.10 HPE
13.11 Huawei
13.12 Red Hat
13.13 Akamai
13.14 Gigaspaces
13.15 Caucho Technology
13.16 APAChe Tomcat
13.17 Tmaxsoft
13.18 Nastel Technologies
13.19 Navisite
13.20 Rogue Wave Software
13.21 4D Technologies
13.22 Nginx
13.23 Mendix
13.24 Kony
13.25 Betty BlocksFor more information about this report visit https://www.researchandmarkets.com/research/59xdk7/11_6_billion?w=12
CONTACT: CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Software Reported by GlobeNewswire 28 minutes ago.

---

Iran tells UN it will hike uranium enrichment capacity, says move does not mean negotiations with Europe have failed

June 5, 2018, 4:12 am

≫ Next: Global Gene Therapy Market Forecast to 2020 with Focus on the United States

≪ Previous: $11.6 Billion Application Platform Market - Global Forecast to 2023

$

0

0

Iran has notified the International Atomic Energy Agency that it has launched a plan to increase its uranium enrichment capacity, nuclear chief Ali Akbar Salehi said Tuesday. Reported by Firstpost 34 minutes ago.

Global Gene Therapy Market Forecast to 2020 with Focus on the United States

June 5, 2018, 4:28 am

≫ Next: Hisense to join fans on the road to Russia with 'See the Incredible Tour'

≪ Previous: Iran tells UN it will hike uranium enrichment capacity, says move does not mean negotiations with Europe have failed

$

0

0

Dublin, June 05, 2018 (GLOBE NEWSWIRE) -- The "Global & US Gene Therapy Market Forecast to 2020" report has been added to *ResearchAndMarkets.com's* offering."Global & US Gene Therapy Market Forecast to 2020, most of the gene therapy researches are being focused on finding the treatment for cancer, followed by genetic diseases and neurological disorders, respectively. In this context, the gene therapy application chapter of the report provides a comprehensive overview of various diseases in which the gene therapy is used, along with the current and future market size of gene therapy for particular disease and its geographical break up.Primarily, the gene therapy market is dominated by oncology applications, with several companies and academic institutions focusing on novel and difficult to treat' cancers. Other therapeutic areas seeking developments in gene therapy include monogenic diseases, cardiovascular diseases, infectious diseases, inherited blindness and neurological diseases. Furthermore, the chapter also provides details regarding the various aspects of the clinical trials in the different gene therapy application by phases, vector types, etc.

The major part of the revenue of gene therapy market is generated from research phase. Most of the gene therapy products are in research phases, only few products have been commercialized till date. The report also provides the sales of major marketed gene therapy products, and the list of the products in clinical/pre-clinical research along with their clinical phases.

The companies operating in the gene therapy market are also receiving various funding, grants, and investment from government bodies and venture capitalist firms which are aiding them to develop new products. The study highlights the applications for which the investments have been received.

North America continues to have the maximum number of clinical trials in the gene therapy segment. This is a major reason for the dominant position of North America in the gene therapy market. Based on the geography, the market is divided into four regions, namely, North America, Europe, Asia, and Rest of the World. The report provides the market for each of the geography, along with its forecast till 2020.

The report further covers how major trends and drivers, mainly gene silencing, advanced therapies combining gene therapy and stem cell technology, immunodeficiency syndromes, growing interest of venture capital firms, etc. will propel the industry's growth. An analysis has also been done of a few factors limiting the growth of the industry. The report also provides insights regarding the strategies adopted by the players from 2013 to 2015 for enhancing their market share. Finally, with a view to understand the competitive landscape, the profiles of key market players have been included in the report to present a complete picture of the global gene therapy market.

*Key Topics Covered:*
1. Analyst View

2. Research Methodology

3. Gene Therapy - An Introduction
3.1 Classification of Gene Therapy Techniques
3.2 Physical Methods of Gene Transfer
3.2.1 Electroporation
3.2.2 Hydrodynamic
3.2.3 Microinjection
3.2.4 Particle Bombardment
3.2.5 Ultrasound-Mediated Transfection
3.3 Vectors for Gene Therapy
3.3.1 Viral Vectors
3.3.1.1 Adenoviral Vectors
3.3.1.2 Adeno-associated Virus Vectors
3.3.1.3 Retroviral Vectors
3.3.1.4 Lentiviral Vectors
3.3.2 Non Viral Vectors
3.3.2.1 Naked DNA/Plasmid Vectors
3.3.2.2 Oligonucleotides
3.3.2.3 Liposomes, Lipoplexes and Polyplexes
3.3.2.4 Gene-Activated Matrix

4. Industry Overview
4.1 Market Drivers
4.1.1 Failure of Conventional Therapies to Treat Cancers
4.1.2 Rising Focus to Accelerate Commercialization of Gene Therapy in Developed Nations
4.1.3 Rising Incidence of Chronic and Life-Threatening Diseases
4.1.4 Growing Interest of Venture Capital Firms
4.2 Market Restraints
4.2.1 Stringent Regulatory Laws & Safety Concerns
4.2.2 Challenges in Commercialization of Gene Therapy
4.2.3 High Cost of the Gene Therapy Drugs
4.2.4 Pitfalls in Current Technique
4.2.5 Production & Manufacturing: A Unique Challenge for Gene Therapies
4.3 Market Opportunities
4.3.1 Approval of Gene Therapy Drug in Europe
4.3.2 Gene Therapy for Hemophilia B Offers Significant Opportunity
4.4 Industry Trends
4.4.1 Gene Silencing: Gaining Momentum
4.4.2 Advanced Therapies: Combining Gene Therapy and Stem Cell Technology
4.4.3 Immunodeficiency Syndromes: The Focus of Gene Therapy
4.4.4 Nanotechnology: Empowering Gene Therapy
4.4.5 Gene Therapy: A New Hope to Treat Blindness
4.4.6 Gene Therapy: Potential Cure for Cancer
4.5 Winning Imperatives
4.5.1 Investment in R&D Activities

5. Clinical Trial Assessment & Pipeline Analysis
5.1 Clinical Trials
5.1.1 By Geography
5.1.2 By Indication
5.1.3 By Gene Type
5.1.4 By Vector
5.1.5 By Clinical Trial Phase
5.2 Pipeline Analysis

6. Gene Therapy Market - Regulatory Landscape & Reimbursement Scenario
6.1 Regulatory Landscape
6.1.1 US
6.1.2 Canada
6.1.3 Europe
6.1.4 Japan
6.1.5 China
6.1.6 India
6.1.7 Australia
6.2 Reimbursement Scenario in Global Market

7. Marketed Gene Therapies
7.1 Neovasculgen
7.2 Glybera
7.3 Gendicine, Rexin-G, Oncorine
7.3.1 Gendicine
7.3.2 Rexin G
7.3.3 Oncorine

8. Gene Therapy Market
8.1 Global
8.2 US

9. Gene Therapy Market by Application
9.1 Oncology
9.2 Cardiovascular Diseases
9.3 Infectious Diseases
9.4 Neurological Diseases
9.5 Genetic Diseases
9.6 Others

10. Gene Therapy Market Size by Geography

11. Competitive Landscape
11.1 Strategies Adopted by Various Players
11.1.1 Strategic Collaborations
11.1.2 Acquisitions
11.1.3 Funding & Investments
11.2 Companies Progress in Gene Therapy In 2015*12. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses)*

· Advantagene Inc.
· Bluebird Bio
· Genethon
· Human Stem Cells Institute
· Oxford BioMedica Plc
· Sanofi
· Shanghai Sunway Biotech Co. Ltd.
· Sibiono GeneTech Co. Ltd.
· Spark Therapeutics, LLC
· uniQure N.V.
· Vical Inc.
· ViroMed Co. Ltd. dba VM BioPharma

For more information about this report visit https://www.researchandmarkets.com/research/jcsvr6/global_gene?w=12
CONTACT:

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics Reported by GlobeNewswire 18 minutes ago.

Hisense to join fans on the road to Russia with 'See the Incredible Tour'

June 5, 2018, 4:32 am

≫ Next: Global shares bounce back on strong China economic data

≪ Previous: Global Gene Therapy Market Forecast to 2020 with Focus on the United States

$

0

0

QINGDAO, China, June 5, 2018 /PRNewswire/ -- Hisense, official sponsor of the 2018 FIFA World Cup^TM and official television of the tournament, today announced that it is taking to the road and bringing its 'See the Incredible Tour' content to football fans across Europe. As a proud sponsor, Hisense will provide unique opportunities for fans across the globe to see and engage online with 'incredible' FIFA World Cup video content and stories throughout the whole tournament.Hisense See the Incredible Tour

Starting in Spain on the 14th June and travelling through France, England, Germany all the way to Russia, Hisense and Lloyd Griffith, comedian and passionate goalkeeper will use social media including Facebook Live shows, Instagram, Twitter and YouTube to introduce the 'incredible' countries, people and moments during the FIFA World Cup.

Joined by World Cup legends including Luís Figo, Robert Pires, Michael Owen, Benedikt Höwedes and Marcel Desailly, as well as local social media influencers and freestylers, Hisense will build a social movement and constant stream of humorous and 'incredible' video content following the excitement of the FIFA World Cup, amplified through the channels of all those involved. They will also be encouraging fans across the world to share their 'incredible' personal moments supporting their country, using the hashtag #sharetheincredible. Fans who use the hashtag and tag @HisenseSports will be in the chance to win an 'incredible' Hisense 4K HDR ULED TV, 2018 FIFA World Cup^TM memorabilia or tickets to the FIFA World Cup Final.

Its fully branded and product-equipped Hisense tour bus will make its way through Europe in the group stages, to Russia in the knockout stages and ultimately the FIFA World Cup Final, with special guests along the way pushing 'incredible' on the ground activities to the world through social media.

A world-leading consumer electronics and home appliances company, headquartered in Qingdao, China, Hisense is the first ever Chinese consumer electronic brand to sponsor the tournament. Through the partnership Hisense will use its global marketing activations including the 'See the Incredible Tour' to engage with fans and bring them closer to the action through its 4K HDR ULED televisions while on the road.

Lloyd Griffith said: "I'm absolutely buzzing to be part of Hisense's 'See the Incredible Tour'! As a huge football fan, attending the World Cup will probably be the biggest moment of my life, up there with Grimsby Town versus Forest Green. I'm excited to meet other fans and hear all the incredible FIFA World Cup stories and moments out there - I'm sure we're going to have some mega lols along the way too. I may not have made the England squad, but I'm over the moon to be on the bus to Russia with Hisense. I'd better start brushing up on my Spanish and French and German... and Russian lingos!"

Hisense's sponsorship with the 2018 FIFA World Cup^TM is a significant sports marketing event partnership. As Hisense expands its brand awareness, sports marketing continues to play a very important role in improving the Hisense brand worldwide.

More information about Hisense's See the Incredible campaign can be found at seetheincredible.com.     

*About Hisense*

Founded in 1969, Hisense is one of the largest consumer electronic and home appliances company with 18 overseas branches in the world. Hisense offers an innovative range of technology driven products that are manufactured and distributed across the world including smart TVs, smart phones, refrigerators, freezers, and air conditioners, among other products.

Photo - https://photos.prnasia.com/prnh/20180605/2151813-1 Reported by PR Newswire Asia 15 minutes ago.

Global shares bounce back on strong China economic data

June 5, 2018, 4:39 am

≫ Next: Zai Lab Expands Commercial Leadership Team, Appoints William Liang as Chief Commercial Officer

≪ Previous: Hisense to join fans on the road to Russia with 'See the Incredible Tour'

$

0

0

Shares were mostly higher in Europe on Tuesday after a mixed day in Asia, as strong economic data from China suggested global growth is on the uptick. Reported by Newsday 8 minutes ago.

Zai Lab Expands Commercial Leadership Team, Appoints William Liang as Chief Commercial Officer

June 5, 2018, 4:38 am

≫ Next: InflaRx Opens New Research Facility in Ann Arbor

≪ Previous: Global shares bounce back on strong China economic data

$

0

0

SHANGHAI, China, June 05, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that William Liang has been appointed Chief Commercial Officer, reporting to Dr. Samantha Du, Zai Lab’s Chief Executive ­­Officer. Mr. Liang brings more than two decades of experience in the pharmaceutical industry, heading China and regional commercial operations of global companies, with expertise in commercial launch, strategy and operations. William was instrumental in establishing market-leading oncology and other franchises in China for AstraZeneca and Roche, overseeing commercial success of top selling drugs such as, but not limited to, Tagrisso®, Iressa®, Tarceva®, MabThera®, Herceptin®, Avastin® and Pegasys®.“William is an accomplished leader in the pharmaceutical sector, particularly in China, with a clear, proven track record and relevant experience to support the progress of our product portfolio through commercialization,” said Dr. Du. “Zai Lab is moving into commercial stage this year with the anticipated launch of our first commercial product, ZL-2306, in Hong Kong, and we are looking forward to working closely with William to start building out our China commercial platform across our broad portfolio covering multiple therapeutic areas. We already have six programs in late-stage development and expect several important clinical milestones this year. We will continue to further expand and strengthen our position as the ‘Gateway for China’ for our strategic partners, while advancing our in-house discovery efforts.”

Prior to joining Zai Lab, William served as Vice President at AstraZeneca heading up the Oncology Business Unit in China. Under his leadership, AstraZeneca built a top performing oncology franchise in China by significantly outgrowing the market with many successful product launches, including setting a new benchmark for the successful market launch of Tagrisso®. During his tenure, Mr. Liang expanded his team from approximately 500 to 2,000 professionals and introduced a patient-centric business model to establish AstraZeneca’s oncology leadership position in China. Prior to AstraZeneca, he was Vice President of Oncology at Bristol-Myers Squibb in China, where he rebuilt the oncology sales team to achieve substantial sales growth. Previously, he spent over 13 years in senior commercial roles at Roche, where he began his career and ultimately achieved the position of China Business Unit Director of Oncology. Mr. Liang received his Medical Degree in Clinical Medicine from Fudan University and his Executive MBA degree from the China Europe International Business School.

“I am very excited to join Samantha and the talented team at Zai Lab, a leading biopharmaceutical company with an exceptional track record and reputation for advancing clinically important therapeutics for the China and global markets,” commented Mr. Liang. “I wholeheartedly share the Company’s vision to become a fully integrated biopharmaceutical company, developing, manufacturing and commercializing transformative medicines to address significant, unmet clinical demand.  We have the opportunity to build two leading therapeutic franchises in China, one in oncology and one in infectious diseases with multiple Category I innovative medicines coming to the market.”

*About Zai Lab*
Zai Lab (NASDAQ:ZLAB) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. The company’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China’s pharmaceutical market and global unmet medical needs. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners’ and its own products in order to impact human health worldwide.

*Zai Lab Forward-Looking Statements*
This press release includes certain disclosures which contain "forward-looking statements," including, without limitation, statements regarding the commercialization of ZL-2306. You can identify forward-looking statements because they contain words such as "anticipate" and "expected." Forward-looking statements are based on Zai Lab's current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Zai Lab's Annual Report on Form 20-F for the fiscal year ended December 31, 2017, and its other filings with the Securities and Exchange Commission. Zai Lab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

*Contact:*

*Zai Lab*
Billy Cho
+86 137 6151 2501
billy.cho@zailaboratory.com

Media: Justin Jackson
Burns McClellan, on behalf of Zai Lab
212-213-0006, ext. 327, jjackson@burnsmc.com

Investors: Jill Steier
Burns McClellan, on behalf of Zai Lab
212-213-0006, ext. 367, jsteier@burnsmc.com  Reported by GlobeNewswire 8 minutes ago.

InflaRx Opens New Research Facility in Ann Arbor

June 5, 2018, 4:38 am

≫ Next: $1 Billion Friction Modifiers Market, 2022 by Type (Organic and Inorganic), Application (Transportation Lubricants (Commercial Vehicle, Passenger Vehicle, Aviation, Marine), and Industrial Lubricants)

≪ Previous: Zai Lab Expands Commercial Leadership Team, Appoints William Liang as Chief Commercial Officer

$

0

0

R&D activities will focus on proprietary complement science
Site will be overseen by InflaRx Chief Scientific Officer

JENA, Germany, June 05, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing innovative therapeutics to treat life-threatening inflammatory diseases by targeting the complement system, a key component of the innate immune system, announced they have opened a new research facility in Ann Arbor, Michigan, in the United States. The facility will be part of InflaRx Pharmaceuticals Inc., a wholly owned US subsidiary of the InflaRx N.V. group, and operations will serve to further develop and extend the Company’s unique complement system-based therapeutics.“At InflaRx, our primary focus is to discover and develop complement-based therapeutics that can change the way inflammatory diseases are treated by providing innovative solutions for patients with currently unmet medical needs,” said Prof. Niels Riedemann, MD, Chief Executive Officer of InflaRx. “The opening of InflaRx’s new research site in Ann Arbor, the city where our co-founder and CSO, Renfeng Guo, and I met and conducted our post-graduate studies researching the complement system, highlights the Company’s strong connection to cutting edge science and dedication to innovation.” 

InflaRx Chief Scientific Officer, Dr. Renfeng Guo commented: “The Company’s return to its scientific origins in Ann Arbor by opening this research facility is a significant milestone for InflaRx that will afford us significant advantages as we focus on our mission of discovering and developing superior treatments for inflammatory conditions. I am thrilled to have the opportunity to drive the site’s operations and look forward to taking full advantage of our new capabilities as we accelerate and broaden our pipeline.”

Following InflaRx’s successful initial public offering on the Nasdaq exchange in November of last year and the recent successful follow-on offering, the opening of this research facility represents the continued growth of the Company’s presence in the US. The opening comes at a time when the Company’s lead candidate, IFX-1 is advancing through clinical trials with phase 2B data for its lead indication, hidradenitis suppurativa, expected in the first half of 2019.

*About IFX-1:
*IFX-1 is a first-in-class monoclonal anti-complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood. Thus, IFX-1 leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5. IFX-1 has demonstrated control of the inflammatory response driven tissue and organ damage by specifically blocking C5a as a key “amplifier” of this response in pre-clinical studies. IFX-1 is the first monoclonal anti-C5a antibody introduced into clinical development that has, to date, successfully completed three clinical Phase II studies. In total, more than 150 patients have so far been treated with IFX-1, which was well tolerated. IFX-1 is currently being developed for different inflammatory indications.

*About InflaRx N.V.:
*InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and has offices in Jena and Munich, Germany. InflaRx is listed on the Nasdaq Global Select Market in the United States under the trading symbol “IFRX”. For further information please visit www.inflarx.com.

*Contacts:*
*InflaRx N.V.*
Prof. Dr. Niels C. Riedemann, CEO
info@inflarx.de
+49 3641 508180

Arnd Christ, CFO
info@inflarx.de
+49 89 4141897800

*Investor Relations*
*LifeSci Advisors*
Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254

*Media US*
*LifeSci Public Relations*
Matt Middleman, M.D.
matt@lifescipublicrelations.com
+1 646 627 8384

*Media Europe*
*MC Services AG           *
Katja Arnold, Andreas Jungfer
inflarx@mc-services.eu
+49 89 210 2280

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “estimate,” “predict,” “potential” or “continue” and similar expressions. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our intellectual property position, our ability to develop commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us and the risks uncertainties and other factors described under the heading “Risk Factors” in InflaRx’s periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law. Reported by GlobeNewswire 8 minutes ago.

$1 Billion Friction Modifiers Market, 2022 by Type (Organic and Inorganic), Application (Transportation Lubricants (Commercial Vehicle, Passenger Vehicle, Aviation, Marine), and Industrial Lubricants)

June 6, 2018, 3:45 am

≫ Next: 10 things you need to know before the opening bell (SPY, SPX, QQQ, DIA, TWTR, SNAP, TSLA)

≪ Previous: InflaRx Opens New Research Facility in Ann Arbor

$

0

0

Dublin, June 06, 2018 (GLOBE NEWSWIRE) -- The "Friction Modifiers Market by Type (Organic and Inorganic), Application (Transportation Lubricants (Commercial Vehicle, Passenger Vehicle, Aviation, Marine), and Industrial Lubricants), and Region - Global Forecast to 2022" report has been added to *ResearchAndMarkets.com's* offering.The friction modifiers market is projected to grow from USD 843.0 million in 2017 to USD 1,004.3 million by 2022, at a CAGR of 3.6% during the forecast period.Friction modifiers are also termed as antifriction additives. APAC is the manufacturing hub for automotive due to the increasing vehicle production in China and India. The growth of the friction modifiers market can be attributed to the continuous growth of the transportation industry in these emerging economies. In addition, governments in these countries are focusing on infrastructural developments such as building new road highways, ports, airports, railway infrastructure, and social infrastructure. Such factors are expected to impact the friction modifiers market in industrial as well as transportation lubricants applications. However, the introduction of electrical vehicles and alternate fuels act as challenges for the growth of the friction modifiers market.

Inorganic friction modifiers are the most widely used type of friction modifiers, as they enhance the life as well as the quality of lubricants wherein they are applied. Inorganic additives are cheaper than organic friction modifiers. Molybdenum compounds subsegment is estimated to account for the largest share of the inorganic friction modifiers in 2017.

The transportation lubricants segment is further segmented into commercial vehicle, passenger vehicle, aviation, and marine. The passenger vehicle subsegment is expected to grow at the highest CAGR between 2017 and 2022. The high growth of the friction modifiers market is expected due to the increasing environmental and safety concerns. The increasing use of friction modifiers in transportation lubricants can help reduce greenhouse gas emissions and other types of environmental pollution.

The friction modifiers market has been studied for North America, Europe, Asia Pacific, South America, and the Middle East & Africa. The Asia Pacific region is expected to lead the friction modifiers market during the forecast period, owing to the increasing demand from emerging economies such as China, India, and South Korea due to the growing transportation sector and industrialization. Furthermore, due to the presence of major lubricant manufacturing companies in the region, the friction modifiers market is expected to witness significant growth in the region. The Asia Pacific friction modifiers market is also projected to grow at the highest CAGR between 2017 and 2022, in terms of value.*Key Topics Covered:**1 Introduction*

*2 Research Methodology*

*3 Executive Summary *

*4 Premium Insights*
4.1 Significant Opportunities in Friction Modifiers Market
4.2 APAC Friction Modifiers Market, By Application and Country
4.3 Friction Modifiers Market, By Type
4.4 Friction Modifiers Market Attractiveness

*5 Market Overview*
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Growing Automotive Industry and Vehicle Parc
5.2.1.2 Increasing Demand for Fuel-Efficient Lubricants
5.2.2 Restraints
5.2.2.1 Rise in Demand for Alternative Fuels
5.2.3 Opportunities
5.2.3.1 Stringent Environmental Regulations
5.2.3.2 Advancements in Friction Modifier Additive Technologies
5.2.4 Challenges
5.2.4.1 Shift Toward Fully Electric Vehicles
5.3 Porter's Five Forces Analysis
5.3.1 Threat of Substitutes
5.3.2 Threat of New Entrants
5.3.3 Bargaining Power of Suppliers
5.3.4 Bargaining Power of Buyers
5.3.5 Intensity of Competitive Rivalry
5.4 Macroeconomic Indicators
5.4.1 GDP Growth Rate Forecast of Major Economies
5.4.2 Trends and Forecast of Oil & Gas Industry
5.4.3 Trends and Forecast of Infrastructure Industry
5.4.4 Trends and Forecast of Automotive Industry

*6 Friction Modifiers Market, By Type*
6.1 Introduction
6.2 Organic Friction Modifiers
6.2.1 Fatty Acids
6.2.2 Esters & Amides
6.2.3 Functional Polymers
6.3 Inorganic Friction Modifiers
6.3.1 Molybdenum Compounds
6.3.2 Nanoparticles

*7 Friction Modifiers Market, By Application*
7.1 Introduction
7.2 Transportation Lubricants
7.2.1 Commercial Vehicle Lubricants
7.2.2 Passenger Vehicle Lubricants
7.2.3 Aviation Lubricants
7.2.4 Marine Lubricants
7.3 Industrial Lubricants

*8 Friction Modifiers Market, By Region*

*9 Competitive Landscape*
9.1 Overview
9.2 Market Ranking Analysis
9.2.1 Lubrizol
9.2.2 Afton
9.2.3 Infineum
9.2.4 Chevron Oronite
9.2.5 Croda
9.3 Competitive Scenario
9.3.1 Expansion
9.3.2 New Product Launch
9.3.3 Acquisition

*10 Company Profiles*
10.1 Lubrizol Corporation
10.2 Afton Chemical Corporation
10.3 Infineum International Limited
10.4 Chevron Oronite Company LLC
10.5 Croda International PLC
10.6 BASF SE
10.7 Chemtura Corporation
10.8 Kings Industries, Inc.
10.9 BRB International BV
10.10 Vanderbilt Chemicals, LLC
10.11 Other Market Players
10.11.1 CSW Industrials Inc.
10.11.2 Abitec Corporation
10.11.3 Wynn's
10.11.4 Adeka Corporation
10.11.5 Archoil
10.11.6 Multisol Ltd.
10.11.7 PMC Biogenix, Inc.
10.11.8 Nyco SA
10.11.9 Dog Deutsche Oelfabrik Gesellschaft Fr Chemische Erzeugnisse Mbh & Co. Kg
10.11.10 Akzonobel N.V.For more information about this report visit https://www.researchandmarkets.com/research/z53zl6/1_billion?w=12
CONTACT: CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Lubricants and Greases Reported by GlobeNewswire 1 hour ago.

---

10 things you need to know before the opening bell (SPY, SPX, QQQ, DIA, TWTR, SNAP, TSLA)

June 6, 2018, 4:12 am

≫ Next: EU warns UK-centered China import scam may shift to Europe’s ‘Silk Road’

≪ Previous: $1 Billion Friction Modifiers Market, 2022 by Type (Organic and Inorganic), Application (Transportation Lubricants (Commercial Vehicle, Passenger Vehicle, Aviation, Marine), and Industrial Lubricants)

$

0

0

Here is what you need to know. 

*The world's biggest hedge fund warns: '2019 is setting up to be a dangerous period for the economy.' *Ray Dalio's Bridgewater Associates said in a note to clients seen by Business Insider that it's "bearish on almoast all financial assets." 

*The annual Bilderberg Meeting is happening this week. *The Bilderberg Meeting, which hosts powerful politicians, financiers, and CEOS from Europe and North America, takes place in Turin, Italy this week and populism is at the top of the agenda.

*Chinese tech company ZTE may pay a $1.7 billion fine. *The US Commerce department would lift sanctions on ZTE that prevents it from buying US suppliers if the fine is paid, Reuters reports.

*A H0ng Kong parking space sold for $760,000. *The parking space, which is located at the luxury Ultima project in Hong Kong's Kowloon district, was bought for just $430,000 less than a year ago. 

*Investors are stubbornly clinging to a trade that blew up earlier this year — and Morgan Stanley says they’re setting themselves up for more carnage. *Traders betting against volatility haven't learned their lesson and they're at risk of repeating the same mistake they made earlier this year, according to Morgan Stanley strategist Phanikiran Naraparaju.

*Elon Musk says Tesla is close to reaching its Model 3 production goals. *"I think it's quite likely we'll achieve a 5,000 car week by the end of this month," Musk said at Tesla's annual shareholder meeting on Tuesday, adding, "This is like ... the most excruciating, hellish several months I've maybe ever had."*Twitter surges after being added to the S&P 500.* Twitter gained 5.2% Tuesday, hitting its best level in three years after S&P Global announced it would replace Monsanto in the S&P 500 

*Snap is on a 5-day winning streak. *Shares of Snap have gained more than 22% since the streak began last Wednesday.

*Stock markets around the world are higher. *Hong Kong's Hang Seng (+0.53%) paced the gains in Asia and Germany's DAX (+0.51%) is out front in Europe. The S&P 500 is set to open up 0.22% at 2,755. 

*US economic data trickles out. *The trade balance will be released at 8:30 a.m. ET. The US 10-year yield is up 2 basis points at 2.95%.

Join the conversation about this story » Reported by Business Insider 54 minutes ago.

EU warns UK-centered China import scam may shift to Europe’s ‘Silk Road’

June 6, 2018, 3:47 am

≫ Next: European TV Gets Ready to Fight Netflix, HBO

≪ Previous: 10 things you need to know before the opening bell (SPY, SPX, QQQ, DIA, TWTR, SNAP, TSLA)

$

0

0

European Union anti-fraud investigators suspect Greece and Hungary may have become the main EU centers of a multi-million-euro scam involving imports of Chinese clothing and footwear that uses the infrastructure of China’s new “Silk Road”. The large-scale fraud, which involves... Reported by EurActiv 1 hour ago.

European TV Gets Ready to Fight Netflix, HBO

June 6, 2018, 3:53 am

≫ Next: EU to impose retaliatory tariffs on US imports from July

≪ Previous: EU warns UK-centered China import scam may shift to Europe’s ‘Silk Road’

$

0

0

Netflix this year is doubling its European programming budget, to $1 billion; Amazon will soon have at least a dozen original series from Europe, up from one in 2014. And HBO  is boosting its non-U.S. offerings this year by 40%, to 250 hours of shows. These newcomers could spur a mass defection of viewers to the increasingly more convenient web, and Europe’s traditional broadcasters are scrambling to find a response. Reported by TVNewsCheck 1 hour ago.

EU to impose retaliatory tariffs on US imports from July

June 6, 2018, 3:51 am

≫ Next: Business growth will not be constrained by stricter work visa norms: Infosys

≪ Previous: European TV Gets Ready to Fight Netflix, HBO

$

0

0

BRUSSELS (AP) — The European Union says it will start imposing duties from July on a list of U.S. products in response to President Donald Trump's decision to slap tariffs on steel and aluminum imports from Europe. European Commission Vice-President Maros Sefcovic said Wednesday that formalities in finalizing the list should be completed this month and that "the new duties start applying from July." The EU says it will introduce "rebalancing" tariffs on about 2.8 billion euros' ($3.4 billion) worth of U.S. steel, agricultural and other products, including bourbon, peanut butter, cranberries and orange juice. The European Union exported some 5.5 million tons of steel to the U.S. last year. Reported by SeattlePI.com 1 hour ago.

Business growth will not be constrained by stricter work visa norms: Infosys

June 6, 2018, 4:05 am

≫ Next: Biz growth won't be hit by stricter visa norms: Infy

≪ Previous: EU to impose retaliatory tariffs on US imports from July

$

0

0

"I think, in general what we see in many of our markets -- Europe, Australia, New Zealand, US market -- independent from the current political situation -- the overall sentiment is to enhance more local jobs activities," Infosys CEO Salil Parekh said at Morgan Stanley's 20th Annual India Summit. Reported by IndiaTimes 1 hour ago.

Biz growth won't be hit by stricter visa norms: Infy

June 6, 2018, 4:29 am

≫ Next: Calero Software Acquires United Kingdom-based Veropath

≪ Previous: Business growth will not be constrained by stricter work visa norms: Infosys

$

0

0

"I think, in general what we see in many of our markets -- Europe, Australia, New Zealand, US market -- independent from the current political situation -- the overall sentiment is to enhance more local jobs activities," Infosys CEO Salil Parekh said at Morgan Stanley's 20th Annual India Summit. Reported by IndiaTimes 37 minutes ago.

Calero Software Acquires United Kingdom-based Veropath

June 6, 2018, 4:03 am

≫ Next: OptDyn™ Welcomes David Drake to Advisory Board as it Aims to Conquer the Cloud

≪ Previous: Biz growth won't be hit by stricter visa norms: Infy

$

0

0

Acquisition more than doubles the company’s European-based personnel and expertise supporting Telecom Expense Management for European and Multi-National Clients

ATLANTA, Ga. and EDINBURGH, Scotland (PRWEB) June 06, 2018

Calero Software LLC, a leading global provider of Communications and Cloud Lifecycle Management (CLM) software and managed services, including Telecom Expense Management (TEM), Managed Mobility Services (MMS) and Usage Management, announced today that it has acquired Veropath Ltd. Headquartered in Edinburgh, Scotland, Veropath is a leading provider of TEM solutions throughout the U.K. and Europe. Financial terms were not disclosed.

The United Kingdom is the second largest TEM market globally. “The addition of Veropath more than doubles Calero’s European team, further strengthening our market position within the EMEA region,” stated Chris Jurasek, President and CEO of Calero. “With Veropath and our acquisition of A&B Groep earlier this year, Calero offers the most robust European in-market expertise, an unparalleled understanding of the nuances associated with doing business in EMEA, and one of the industry’s most comprehensive global solutions and services portfolios.”

David Booker, CEO of Veropath and now Managing Director for Calero added, “I’m thrilled to partner with Riverside Partners and to join the Calero team. As the Veropath solution becomes part of the broader Calero offering, Veropath clients will benefit greatly from Calero’s market-leading position, a shared view on delivering excellent customer value, its commitment to innovation, and a complementary set of solutions designed to help enterprises manage cloud expenses, mobile services and usage optimization. At the same time, our clients can expect no change to their existing solutions or the high levels of service they experience from Veropath.”

“Veropath represents continued investment in strategic geographies for CLM from the Calero and Riverside Partners team. Our commitment to Calero as a leading CLM platform extends to supporting our clients with industry leading localized knowledge, sales and support resources. Veropath delivers in all three areas,” stated Michelle Noon, General Partner at Riverside Partners. “Furthermore, Calero’s clients will benefit from leading edge technology and resources available to address global security and privacy concerns including the recently implemented GDPR requirements.”

“This transaction is one of a few carefully chosen strategic acquisitions designed to add scale, enhance client service and broaden Calero’s technology and service offerings while carefully maintaining a one-company global approach,” said Steven F. Kaplan, Chairman of Calero and General Partner at Riverside Partners. “It is further proof that Calero is quickly delivering on its goal to be the CLM provider of choice for domestic and multi-national corporations worldwide.”

Calero’s software and managed service solutions deliver sustainable value within large enterprises, universities and government agencies by enabling clients to more efficiently and more effectively manage the myriad of cloud and communications services, devices, contracts, invoices and spending across their operations. Today, Calero manages more than $7 billion of annual telecom, mobility and cloud spend for over 3,000 customers operating in more than 50 countries globally. Calero also provides managed mobility services for more than 500,000 mobile devices.

ABOUT CALERO, LLC
Calero is a leading provider of Communications and Cloud Lifecycle Management (CLM) solutions designed to turn communication data into actionable insight by simplifying the management of voice, mobile and other unified communications services and assets. With a deep commitment to innovation and customer service, Calero’s CLM approach enables organizations to support the full communications lifecycle, from procurement to payment, including software and services that aid Telecom Expense Management (TEM), Managed Mobility Services (MMS) and Usage Management. Calero has thousands of customers in over 50 countries worldwide, including Fortune 2000 corporations, universities and government agencies. Calero is a portfolio company of Riverside Partners, a Boston-based private equity firm. Learn more at http://www.calero.com.

ABOUT VEROPATH LTD
Veropath is a leading provider of Information Technology Expense Management (TEM) services for International enterprise clients – addressing the challenge of managing complex IT and telecom estates, to reduce costs and drive efficiencies. Servicing clients in over 30 countries with more than 90 carriers, our Microsoft Azure-based analytics portal gives full visibility of the entire asset base, identifying all types of unnecessary expenditure to enable accurate, informed budgeting and decision-making. Using this detail we make significant savings, optimize and efficiently manage the lifecycle of the entire IT and telecom estate. Learn more at http://www.veropath.com.

ABOUT RIVERSIDE PARTNERS LLC
Founded in 1989, Riverside Partners is a middle market private equity firm currently investing Riverside Fund V, L.P. The fund focuses on growth-oriented companies primarily in the healthcare and technology industries. Riverside Partners is particularly experienced at partnering with founders, owners and management teams and it brings substantial domain expertise and operating experience to its portfolio companies. For more information visit http://www.riversidepartners.com. Reported by PRWeb 1 hour ago.

---

OptDyn™ Welcomes David Drake to Advisory Board as it Aims to Conquer the Cloud

June 6, 2018, 4:05 am

≫ Next: Plug Power Acquires American Fuel Cell (AFC); Research and Development Capabilities Expand in On-Road Applications Including Delivery Vehicle Fleets

≪ Previous: Calero Software Acquires United Kingdom-based Veropath

$

0

0

Acclaimed LDJ Capital Chairman and Blockchain, Cryptocurrency, and ICO Expert David Drake joins OptDyn™ Advisory Board

New Castle, DE, June 06, 2018 (GLOBE NEWSWIRE) -- OptDyn™, makers of Subutai™, the world’s first intelligent Blockchain enabled Peer-to-Peer (P2P) Cloud computing platform, today announced that David Drake has joined the company’s Advisory Board.David Drake is a lauded proponent for blockchain, cryptocurrency, and ICOs (initial coin offerings). Recognizing the value of digital assets long before becoming ubiquitous, Drake collaborated on the JOBS Act in 2011 to create new laws underlying all ICO fundraising in the United States. His $200M LDJ Cayman Fund focuses on cryptocurrency, mining, and ICO acquisitions. He joins advisors Simon Cocking, Jeff Carr, David Rusling, and Benedict O’Mahoney, who provide expertise in blockchain/cryptocurrency market, Cloud computing, Internet of Things (IoT) and blockchain law respectively.

Drake says, "As with any online business, security has always been a priority. Many have been questioning the performance of the Cloud computing platform amidst all the hacking. Subutai, OptDyn’s brainchild, has the potential to provide the security that large companies are looking for, in a decentralized ecosystem. I am excited to be part of their advisory board and share my expertise of the crypto world."

"OptDyn continues to attract and engage the best of breed professionals in the Cloud and Blockchain communities," said Alex Karasulu, CTO and Founder of OptDyn. "David is one of the most respected and capable advisors and investors in the industry. We are honored to be working with him and LDJ Capital."

Drake, through his family office LDJ Capital, has acted as GP and LP investor with his partners in fund-of-funds, realty funds, venture capital funds, and hedge funds. Drake's investments currently have 50+ global directors that maintain relations with institutions and family offices with access to over a trillion in assets.

Drake, through LDJ Capital, manages and co-invests in alternative assets with the top 30 family offices out of his 5,000 family office and institutional investor reach. These top 30 are 40% from Asia, 20% from Europe, 20% from the Americas, and 20% from the Middle East.

Drake’s access with 100,000 investors is maintained through his media asset, The Soho Loft Media Group, which has produced & sponsored over 1500+ finance conferences since 2002 like the events with institutional media leader Thomson Reuters and with sponsors from NASDAQ, NYSE, KKR, and the Carlyle Group.

LDJ Special Situations partners have invested $100 Million in Alibaba and Palantir.  LDJ Real Estate strategy is set to acquire Class A core rental properties and hotels.

Drake is a digital automation advocate for private equity as he lobbied the US Congress on the JOBS Act since 2011. He represented the US Commerce Department at the EU Commission in Brussels and Rome in 2012, was invited to the White House Champions of Change ceremony in Washington, D.C., and, was a speaker at the UK Parliament in 2013.

*About Subutai™*
Subutai, the world's first intelligent Peer-to-Peer Cloud computing platform, opens the $760+B Cloud and Internet-of-Things ecosystem through decentralized, self-adaptive, and cost efficient infrastructure that connects end users and devices more effectively along the continuum. Developed by Open Source trailblazers, Subutai disrupts and democratizes the Cloud, allowing users to easily participate in the crypto economy through energy-efficient cryptocurrency mining and frictionless commoditization of idle computing resources. Businesses using Subutai can instantly raise and operate a sharing economy for countless applications using KHAN™, its Ethereum blockchain reserve currency token. Subutai is being deployed across the $1.5T global telecommunications and $60B Web Hosting/ISP markets, among many other industries. Visit https://subutai.io/ and https://twitter.com/Subutai_KHAN for more information.

*About OptDyn, Inc.*
Founded in 2013, OptDyn is the company behind Subutai™, the intelligent platform that brings Open Source Peer-to-Peer (P2P) Cloud computing, Internet of Things (IoT), and cryptocurrency mining for everyone. Unlike many companies whose promises lack a working product backing their claims, Subutai is proven, mature (v7.0), solves real-world problems, and is ready to use today. OptDyn is based in the United States with distributed teams in Europe, Asia, and South America. For more information, visit https://optdyn.com/ and https://twitter.com/optdyn© OptDyn, 2018. "OptDyn", "Subutai" and "KHAN" are trademarks of OptDyn, Inc. "Subutai PeerOS", "Subutai Bazaar", "Subutai  Blockchain-in-a-Box", and "Subutai Blockchain Router" are branded products of OptDyn, Inc. All other company and product names may be trademarks of the respective companies with which they are associated.

# # #

*Attachment*

· David Drake

CONTACT: Sally Khudairi
Director
OptDyn
sk@optdyn.com
+1-617-921-8656 Reported by GlobeNewswire 1 hour ago.

Plug Power Acquires American Fuel Cell (AFC); Research and Development Capabilities Expand in On-Road Applications Including Delivery Vehicle Fleets

June 6, 2018, 4:05 am

≫ Next: Fabrick launches to create Open Banking ecosystem

≪ Previous: OptDyn™ Welcomes David Drake to Advisory Board as it Aims to Conquer the Cloud

$

0

0

As global adoption of electric fleet vehicles accelerates in the pursuit of cleaner solutions, Plug Power will continue innovating with speed due to specialized R&D teams such as AFC

LATHAM, N.Y., June 06, 2018 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ:PLUG), a leading provider of energy solutions that change the way the world moves, today announced the acquisition of American Fuel Cell, a premier developer of  Membrane Electrode Assembly (MEA) technology, the key catalyst for fuel cells to create power. With this acquisition Plug Power gains innovative, leading edge MEA design capability coupled with specialized system knowledge for on-road applications. This acquisition accelerates the company’s expansion into the on-road industry, inclusive of delivery vehicle fleets that are increasingly utilizing fuel cell or electric powertrains. Frost & Sullivan, the research firm, recently forecasted the electric truck market (global light, medium, and heavy-duty hybrid) to be on track to achieve annual sales of 2.25M units by 2025. With the global push for cleaner solutions for transportation of goods and passengers, and targets for reduced emissions looming in the near future, solutions such as fuel cell powertrains will continue to grow in popularity, requiring extensive innovation in order to ensure that fuel cell technology capabilities continue to lead the market.

Fuel cells provide a unique opportunity to generate clean, efficient electricity coupled with high power density, extended range, and market-leading uptime due to rapid refueling. American Fuel Cell’s highly skilled team of specialists, based in Rochester, NY, apply their years of experience from past positions at General Motors to drive system optimization and MEA development, especially as it relates to on-road applications. The acquisition, although not financially material, expands Plug Power’s knowledge and technology base in this key sector.

"Joining Plug Power enables us to rapidly expand not only our research, development, and manufacturing efforts, but also provide a significant impact in the application of our commercially viable, innovative system solutions to product in the field,” said Daniel O’Connell, CEO, American Fuel Cell. "Plug Power is not only a known innovator with a long-standing commitment to R&D, but the company also has incredible traction with large organizations seeking to identify and capitalize on creating efficiencies in their supply chain. We’re excited to double-down on our product innovation, as well as see first-hand the immediate benefit companies worldwide can derive from the adoption of hydrogen fuel cell technology as part of their efficiency and clean energy efforts.”

Through this acquisition Plug Power will immediately have a facility in Rochester, NY, located in the Eastman Business Park, with all staff of AFC becoming Plug Power employees. This new office represents an expansion of Plug Power’s operations in its home state of New York, a presence that will continue to grow through 2018 and beyond. With this new facility, Plug Power plans to create more job opportunities for the people of Rochester, NY and appreciates the continued support of the state in all its endeavors.

“Each day, we see the role that fuel cells are playing in the increasingly electrified world evolve in a positive direction. At Plug Power we see demand increasing each month, and given our rich R&D legacy, we’re always looking for new technologies and teams that can help to grow our business and remain at the forefront of emerging fuel cell technology,” said Andy Marsh, CEO, Plug Power. “The American Fuel Cell team is an unmatched group of bright thinkers who understand the potential of fuel cells in on-road applications. We’re looking forward to working together to create a cleaner, more efficient future as on-road applications grow, and electric fleet vehicles increasingly become the norm.”  

*About Plug Power Inc.*   
The architect of modern hydrogen and fuel cell technology, Plug Power is the innovator that has taken hydrogen and fuel cell technology from concept to commercialization. Plug Power has revolutionized the material handling industry with its full-service GenKey solution, which is designed to increase productivity, lower operating costs and reduce carbon footprints in a reliable, cost-effective way. The Company’s GenKey solution couples together all the necessary elements to power, fuel and serve a customer. With proven hydrogen and fuel cell products, Plug Power replaces lead acid batteries to power electric industrial vehicles, such as the lift trucks customers use in their distribution centers.  

Extending its reach into the on-road electric vehicle market, Plug Power’s ProGen platform of modular fuel cell engines empowers OEMs and system integrators to rapidly adopt hydrogen fuel cell technology. ProGen engines are proven today, with thousands in service, supporting some of the most rugged operations in the world. Plug Power is the partner that customers trust to take their businesses into the future. Learn more at www.plugpower.com.

*Safe Harbor Statement*
This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties about Plug Power Inc. ("PLUG"), including but not limited to statements about PLUG's expectations regarding growth in Europe, revenue, growth with GenKey customers and its project financing platform. You are cautioned that such statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times that, or by which, such performance or results will have been achieved. Such statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in these statements. In particular, the risks and uncertainties include, among other things, the risk that we continue to incur losses and might never achieve or maintain profitability; the risk that we will need to raise additional capital to fund our operations and such capital may not be available to us; the risk that our lack of extensive experience in manufacturing and marketing products may impact our ability to manufacture and market products on a profitable and large-scale commercial basis; the risk that unit orders will not ship, be installed and/or converted to revenue, in whole or in part; the risk that pending orders may not convert to purchase orders, in whole or in part; the risk that a loss of one or more of our major customers could result in a material adverse effect on our financial condition; the risk that a sale of a significant number of shares of stock could depress the market price of our common stock; the risk that negative publicity related to our business or stock could result in a negative impact on our stock value and profitability; the risk of potential losses related to any product liability claims or contract disputes; the risk of loss related to an inability to maintain an effective system of internal controls or key personnel; the risks related to use of flammable fuels in our products; the cost and timing of developing, marketing and selling our products and our ability to raise the necessary capital to fund such costs; the ability to achieve the forecasted gross margin on the sale of our products; the risk that our actual net cash used for operating expenses may exceed the projected net cash for operating expenses; the cost and availability of fuel and fueling infrastructures for our products; market acceptance of our products, including GenDrive, GenSure and GenKey systems; the volatility of our stock price; our ability to establish and maintain relationships with third parties with respect to product development, manufacturing, distribution and servicing and the supply of key product components; the cost and availability of components and parts for our products; our ability to develop commercially viable products; our ability to reduce product and manufacturing costs; our ability to successfully expand our product lines; our ability to successfully expand internationally; our ability to improve system reliability for our GenDrive, GenSure and GenKey systems; competitive factors, such as price competition and competition from other traditional and alternative energy companies; our ability to protect our intellectual property; the cost of complying with current and future federal, state and international governmental regulations; risks associated with potential future acquisitions; and other risks and uncertainties referenced in our public filings with the Securities and Exchange Commission (the “SEC”). For additional disclosure regarding these and other risks faced by PLUG, see disclosures contained in PLUG's public filings with the SEC including, the "Risk Factors" section of PLUG's Annual Report on Form 10-K for the year ended December 31, 2017. You should consider these factors in evaluating the forward-looking statements included in this presentation and not place undue reliance on such statements. The forward-looking statements are made as of the date hereof, and PLUG undertakes no obligation to update such statements as a result of new information.

*Media Contact *
Kate Gundry
Pluck
617.797.5174
plugpower@pluckpr.com Reported by GlobeNewswire 1 hour ago.

Fabrick launches to create Open Banking ecosystem

June 6, 2018, 4:02 am

≫ Next: EU urges US not to punish European firms over Iran

≪ Previous: Plug Power Acquires American Fuel Cell (AFC); Research and Development Capabilities Expand in On-Road Applications Including Delivery Vehicle Fleets

$

0

0

Within the framework of Money 20/20, Europe’s premier event dedicated to Fintech innovators and visi... Reported by Finextra 1 hour ago.

EU urges US not to punish European firms over Iran

June 6, 2018, 4:09 am

≫ Next: Kerry Logistics Acquires Majority Stake in Saga Italia S.p.A.; Strengthening Project Logistics Capabilities

≪ Previous: Fabrick launches to create Open Banking ecosystem

$

0

0

European signatories to the Iran nuclear deal have written to key US officials, urging them to respect Europe’s commitment to the deal. They stressed that EU firms active in Iran should be spared form sanctions. Reported by Deutsche Welle 57 minutes ago.

Kerry Logistics Acquires Majority Stake in Saga Italia S.p.A.; Strengthening Project Logistics Capabilities

June 6, 2018, 4:11 am

≫ Next: France: Iran's uranium enrichment plans are close to the 'red line'

≪ Previous: EU urges US not to punish European firms over Iran

$

0

0

FRANKFURT, GERMANY /MILAN, ITALY - Media OutReach - 6 June 2018 - Kerry Logistics Network Limited ('Kerry Logistics'; Stock Code 0636.HK) has acquired a majority stake in Saga Italia S.p.A. ('Saga Italia') as part of its ongoing global expansion strategy. With the acquisition of the Milan-based logistics company, Kerry Logistics strengthens its overall service portfolio by adding Saga Italia's specialised know-how in the fields of project logistics, heavy lift services, and material management.

 

The acquisition will also add three new countries to Kerry Logistics' network, namely, the Republic of the Congo, Uganda, and Egypt, as well as new offices in Kazakhstan, Turkmenistan, United Arab Emirates, Russia, and the US.

 

Founded in 1985, Saga Italia provides end-to-end solutions tailored to its customers' project requirements. More than 150 logistics professionals manage projects for multinational corporations across the globe, particularly for customers in the oil and gas industry. Saga Italia's comprehensive range of services also includes a complete suite of international freight forwarding services covering air, ocean, and overland transportation. 

 

Thomas Blank, Managing Director of Europe, Kerry Logistics, said, "With this step, we continue to build upon our expertise in project logistics which currently spreads across China, The Philippines, Indonesia, The Commonwealth of Independent States, and India. Saga Italia's specialised knowledge further strengthens our activities and will support us to tap into the immense business opportunities as more Belt and Road projects get off the ground. With Saga Italia on our team, we are able to provide a platform to consolidate our project logistics capabilities across the globe."

 

Marco Oriolo, owner and Managing Director of Saga Italia, added, "By joining Kerry Logistics our services are leveraged by an extensive network in Asia and Europe. We are looking forward to a successful future as part of the Kerry Logistics team, driving the businesses of our customers through innovative logistics solutions."

 

*About Kerry Logistics Network Limited (Stock Code 0636.HK)*

Kerry Logistics is an Asia-based, global 3PL with the strongest network in Asia. Its core competency is providing highly customised solutions to multinational corporations and international brands to enhance their supply chain efficiency, reduce overall costs and improve response time to market. It currently has more than 1,000 service points in 55 countries and territories, and is managing 52 million sq ft (4.8 million sq m) of land and logistics facilities worldwide, providing customers with high reliability and flexibility to support their expansion and long-term growth. Kerry Logistics Network Limited is listed on the Main Board of the Hong Kong Stock Exchange and is a selected Member of the Hang Seng Corporate Sustainability Index Series 2017-2018.

* *

*About Saga Italia S.p.A.*

Saga Italia is a leading logistics provider specialised in the field of project logistics and material management. Saga Italia provides its customers with high quality logistics services tailored to their projects' requirements. Freight Forwarding is the core business: over the years, Saga Italia has successfully performed door-to-door multimodal transports throughout the world, but has also gained a strong reputation for transports in landlocked and rough terrains.

 

Besides freight forwarding, Saga Italia offers a wide range of value added services to operate as a one-stop source for its customers: from warehousing, customs brokerage, and post order expediting to pre-shipment inspections, material management, site surveys, and feasibility studies.

 

For more information please visit www.sagaitalia.com Reported by Media OutReach 55 minutes ago.